Cetera Investment Advisers Sells 3,189 Shares of Medpace Holdings, Inc. $MEDP

Cetera Investment Advisers reduced its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 15.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 16,881 shares of the company’s stock after selling 3,189 shares during the quarter. Cetera Investment Advisers’ holdings in Medpace were worth $8,106,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of MEDP. Steigerwald Gordon & Koch Inc. bought a new position in Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC bought a new stake in Medpace in the fourth quarter valued at approximately $30,000. Quarry LP bought a new stake in Medpace in the third quarter valued at approximately $35,000. Bayban acquired a new stake in Medpace in the fourth quarter worth $44,000. Finally, Core Wealth Advisors LLC acquired a new stake in Medpace in the fourth quarter worth $47,000. 77.98% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on MEDP shares. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $535.00 price objective on shares of Medpace in a research note on Thursday, July 23rd. Jefferies Financial Group lowered Medpace from a “buy” rating to a “hold” rating and lifted their target price for the stock from $490.00 to $515.00 in a report on Tuesday, July 7th. BMO Capital Markets boosted their target price on Medpace from $400.00 to $600.00 and gave the company a “market perform” rating in a research note on Friday, July 24th. Finally, Weiss Ratings restated a “hold (c+)” rating on shares of Medpace in a report on Thursday, July 2nd. Two analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat.com, Medpace has an average rating of “Hold” and a consensus target price of $584.18.

Medpace Stock Performance

Shares of MEDP opened at $577.11 on Friday. The firm has a market cap of $16.11 billion, a P/E ratio of 33.83, a PEG ratio of 2.58 and a beta of 1.15. Medpace Holdings, Inc. has a twelve month low of $373.00 and a twelve month high of $677.90. The firm’s 50 day moving average price is $507.61 and its two-hundred day moving average price is $493.77.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.98 by $0.27. Medpace had a net margin of 17.67% and a return on equity of 110.15%. The company had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same quarter in the prior year, the firm earned $3.10 earnings per share. The firm’s revenue was up 17.2% compared to the same quarter last year. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. On average, sell-side analysts anticipate that Medpace Holdings, Inc. will post 17.54 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Medpace news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $450.00, for a total value of $7,357,050.00. Following the sale, the general counsel owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, VP Susan E. Burwig sold 7,500 shares of the business’s stock in a transaction dated Tuesday, July 28th. The shares were sold at an average price of $600.00, for a total value of $4,500,000.00. Following the completion of the sale, the vice president owned 62,984 shares in the company, valued at approximately $37,790,400. This trade represents a 10.64% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 31,087 shares of company stock valued at $16,203,054. Company insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.